Archives of Pharmacal Research

  • 제26권11호
  • /
  • Pages.979-983
  • /
  • 2003
  • /
  • 0253-6269(pISSN)
  • /
  • 1976-3786(eISSN)
대한약학회 (The Pharmaceutical Society of Korea)
권호 표지

Pharmacokinetics of Tolbutamide After Oral Administration to Rabbits with Folate-Induced Renal Failure

  • 발행 : 2003.11.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

The pharmacokinetic of tolbutamide was studied after the oral administration to normal rabbits or rabbits with mild to medium folate-induced renal failure. The plasma concentrations of tolbutamide were significantly elevated (p<0.05) during 9 to 24 h in rabbits with mild or medium folate-induced renal failure. Consequently, the area under the plasma concentration-time curves (AUC) was significantly higher in mild (p<0.05) and medium (p<0.01) folate-induced renal failure rabbits (i.e., 2906 $\mu$g/mL$.$h for mild renal failure and 4074 $\mu$g/mL$.$h for moderate renal failure) than that in normal rabbits (i.e., 2295 $\mu$g/mL$.$h). The cumulative urinary excretion of tolbutamide was significantly depressed (p<0.05) in medium folate-induced renal failure rabbits (i.e., 3.3 mg) compared with that in normal rabbits (i.e., 5.9 mg). The elimination rate constant (Kel) of tolbutamide was significantly decreased in medium renal failure rabbits (i.e., 0.027 $h^{-1}$) than that in normal rabbits (i.e., 0.044 $h^{-1}$ ); As a result, the terminal half-life of tolbutamide in medium folate-induced renal failure rabbits (i.e., 25.5 h) was significantly longer (p<0.01) than that in normal rabbits (i.e., 15.7 h). The change in pharmacokinetic parameters is consistent with the hypothesis that the alteration is mediated by the depressed metabolic elimination of the drug by the induction of renal failure. Therefore, these observations indicated that the dosage adjustment may be necessary for tolbutamide in patients with renal insufficiency.

키워드

참고문헌

  1. Ayanoglu, G., A new aspect of serum protein binding of tolbutamide. Int. J. Clin. Pharmcol. Ther. Toxicol., 24(2), 65-68 (1986)
  2. Adir, J., Effects of total plasma concentration and age on tolbutamide plasma protein binding. Clin. Pharmcol. Ther., 31(4), 488-493 (1982) https://doi.org/10.1038/clpt.1982.65
  3. Balant, L. P., Dayer, P., and Faber, J., Consequences of renal insufficiency on the hepatic clearance of some drugs. Int. J. Clin. Pharmacol. Res., 3, 459-474 (1983)
  4. Beck-Nielsen, H., Hj llund, E., and Sorensen, N. S., Sulfonylureas improve insulin binding and insulin action in non-insulin-dependent diabetes mellitus. Diabetes Care, 7(Suppl 1), 100-105 (1984)
  5. Belandger, P. M., The characteristics of the microsomal hydroxylation of tolbutamide. Can. J. Physiol. Pharmacol., 69(3), 400-405 (1991) https://doi.org/10.1139/y91-061
  6. Bailey, C. J., Flatt, P. R. and Marks, V., Drugs inducing hypoglycaemia. Pharmac. Ther., 42, 361-382 (1982)
  7. Dogterom, P., A species comparison of tolbutamide metabolism in precision-cut liver slices from rats and dogs. Quantative and quantitative sex differences. Drug Metab. Dispos., 21(4), 705-709 (1993)
  8. Ferner, R. E. and Chaplin, S., The relationship between the pharmacokinetics and pharmacodynamic effects of oral hypoglycemic drugs. Clin. Pharmacokin., 12, 379-401 (1987) https://doi.org/10.2165/00003088-198712060-00001
  9. Hosker, J. P., Brunett, M. A., and Turner R. C., Sulfonylurea therapy doubles beta-cell response to glucose in Type 2 diabetic patients. Diabetologia., 28, 809-814 (1985) https://doi.org/10.1007/BF00291069
  10. Knodell, R. G., Hall, S. D., and Guengerich, F. P., Hepatic metabolism of tolbutamide. J. Pharmacol. Exp. Ther., 241, 1112-1119 (1987)
  11. Melander, A., Clinical pharmacology of sulfonylureas. Metabolism, 36(Suppl 1), 12-16 (1987) https://doi.org/10.1016/0026-0495(87)90195-8
  12. Melander, A., Sartor, G., and Bitzen, P. O., Serum tolbutamide and chlorpropamide concentrations in patients with diabete melllitus. Br. Med. J., 1, 142-144 (1978) https://doi.org/10.1136/bmj.1.6106.142
  13. Miners, J. O., Smith, K. J., and Veronase M. E., Tolbutamide hydroxylation by human liver microsomes. Biochem. Pharmacol., 37, 1137-1144 (1988) https://doi.org/10.1016/0006-2952(88)90522-9
  14. Page, M. A., Boutagy, J. S., and Shenfield, G. M., A screening test for slow metabolisers of tolbutamide. Br. J. Clin. Pharmacol., 31, 649-654 (1991) https://doi.org/10.1111/j.1365-2125.1991.tb05587.x
  15. Relling, M. V., Aoyma, T., and Meyer, U. A., Tolbutamide and mephenytoin hydroxylation by human cytochrome P-450 in the CY2C subfamilly. J. Pharmacol. Exp. Ther., 252, 442-447 (1990)
  16. Srivastava, P. K., Separation of human liver microsomal tolbutamide hydroxylase and S-mephenytoin 4'-hydroxylase cytochrome p-450 enzymes. Mol. Pharmacol., 401, 69-79 (1991)
  17. Sturgess, N. C., Ashord, M. l., and Cook, D. l., The sulfonylurea receptor may be an ATP-seneitive potassium channel. Lancet., 11, 474-475 (1985)
  18. Schary, W. L. and Rowland, M., Protein binding and hepatic clearance. J. Pharmacokin. Biopharm., 11, 225-43 (1983) https://doi.org/10.1007/BF01061866
  19. Terao, N. and Shen, D. D., Effect of experimental renal failure on the disposition kinetics of L-propranolol in rats. J. Pharmacol. Exp. Ther., 227, 295-301 (1983)
  20. Veronese, M. E., McManus, M. E., and Birkett, D. J., Tolbutamide hydroxylation by human, rabbit and rat liver microsomes and by purified forms of cytochrome P-450. Drug. Metab. Dispos., 18, 356-361 (1990)
  21. Ward, E. A., Ward, G. M., and Turner, R. C., Effect of sulfonylurea therapy on insulin secretion and glucose control of insulin-treated diabetics. Br. Med. J., 283, 278-280 (1981) https://doi.org/10.1136/bmj.283.6286.278
  22. Yamao, Y., Nakagami, H., and Furuhama, K., Pharmacokinetics of tolbutamide following intravenous and oral administrations in rats with obstructive jaundice. Biol. Pharm. Bull., 17, 691-695 (1994) https://doi.org/10.1248/bpb.17.691
  23. Yamaoka, K., Tanigawara, Y., Nakagawa, T., and, Uno T., A pharmacokinetics analysis program for microcomputer. J. Pharm. Dym., 4, 879-883 (1981) https://doi.org/10.1248/bpb1978.4.879